WHO Pharmaceuticals Newsletter 2004, No. 01
(2004; 17 pages) View the PDF document
Table of Contents
Open this folder and view contentsREGULATORY MATTERS
Close this folderSAFETY OF MEDICINES
View the documentANTIEPILEPTICS - ADR update from Australia
View the documentBOTULINUM TOXIN TYPE A - Place in therapy not clearly defined
View the documentCELECOXIB/ROFECOXIB - Acute temporary visual impairment
View the documentDACLIZUMAB - Increased mortality in cardiac transplant patients
View the documentFLUTICASONE - Update on adrenal insufficiency reports
View the documentINTERFERON BETA - Safety information about risk of liver injury
View the documentMETHADONE - Risk of QT prolongation
View the documentMETHOTREXATE - Update on pulmonary effects
View the documentMIRTAZAPINE - ADR update from Australia
View the documentMORPHINE - Accidental overdose of concentrated oral solutions
View the documentNONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) - Postpartum administration may cause hypertension
View the documentPERGOLIDE - Danger of falling asleep during daily activities
View the documentPYRAZINAMIDE & RIFAMPICIN - Serious liver injury with combined use in latent tuberculosis
View the documentSIBUTRAMINE - ADR update
View the documentTOPIRAMATE - Warning about metabolic acidosis
View the documentWARFARIN - Interaction with cranberry juice
Open this folder and view contentsDRUGS OF CURRENT INTEREST
Open this folder and view contentsFEATURE
 

MORPHINE - Accidental overdose of concentrated oral solutions

USA. Accidental overdose of concentrated oral morphine solutions has resulted in serious adverse events and deaths, according to a ‘Dear Healthcare Professional’ letter issued by Elan Pharmaceuticals in the United States. In most cases, oral morphine solutions that were ordered in mg were mistakenly interchanged for mL, resulting in a 20-fold overdose. Elan distributes three concentrated oral solutions containing morphine 20 mg/mL (Roxanol, Roxanol-T and Roxanol 100). In order to prevent medication errors, the company has requested that prescribers write prescriptions for oral morphine solutions clearly stating the required concentration of oral solution, the intended morphine dose in mg and the corresponding volume in mL.

Reference:
‘Dear Healthcare Professional’ letter from Elan Pharmaceuticals, October 2003. Available from URL: http://www.fda.gov

to previous section to next section
 

Last updated: May 3, 2013